Compare VRTX & DHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | DHR |
|---|---|---|
| Founded | 1989 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.6B | 153.6B |
| IPO Year | 2006 | 2007 |
| Metric | VRTX | DHR |
|---|---|---|
| Price | $547.03 | $230.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 32 | 24 |
| Target Price | ★ $578.71 | $259.90 |
| AVG Volume (30 Days) | 1.6M | ★ 3.7M |
| Earning Date | 11-02-2026 | 10-21-2026 |
| Dividend Yield | N/A | ★ 0.71% |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 10.90 | 4.42 |
| Revenue | $2,488,652,000.00 | ★ $19,893,000,000.00 |
| Revenue This Year | $10.43 | $6.89 |
| Revenue Next Year | $10.52 | $7.70 |
| P/E Ratio | ★ $50.37 | $53.15 |
| Revenue Growth | ★ 46.20 | 8.53 |
| 52 Week Low | $410.50 | $160.93 |
| 52 Week High | $568.67 | $242.80 |
| Indicator | VRTX | DHR |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 52.79 |
| Support Level | $461.04 | $214.36 |
| Resistance Level | N/A | $238.29 |
| Average True Range (ATR) | 18.18 | 7.57 |
| MACD | 2.66 | -0.83 |
| Stochastic Oscillator | 66.14 | 57.27 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.